

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Beyond Medical Technologies Inc. (the "Company")
1111 West Hastings Street, 15th Floor
Vancouver, B.C. V6E 2J3

Item 2. Date of Material Change

The date of the material change is February 6, 2025.

Item 3. News Release

A news release with respect to the material change was disseminated through Newsfile Corp. on February 6, 2025.

Item 4. Summary of Material Change

Vancouver, British Columbia - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") has proposed debt settlement agreements with creditors, wherein the company will issue up to 7.9 million common shares at a deemed price of \$0.05 per share to settle outstanding debts totaling up to \$395,000. As part of this transaction, Daniel Liu, the company's CEO and Director, will receive settlement shares, constituting a related party transaction under Multilateral Instrument 61-101. The company also clarifies that Mr. Liu's appointment as CEO and director became effective on February 3, 2025, rather than January 31, 2025, as previously disclosed.

Item 5. Full Description of Material Change

Item 5.1 Full Description of Material Change

Vancouver, British Columbia - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") proposes to enter into debt settlement agreements with creditors of the company, pursuant to which the company will agree to issue to the creditors and the creditors will agree to accept an aggregate of up to 7.9 million common shares of the company at a deemed issue price of five cents per settlement share in full and final settlement of accrued and outstanding indebtedness in the aggregate amount of up to \$395,000.

The issuance of settlement shares to Daniel Liu, Chief Executive Officer and a director of the company, will be considered to be a related party transaction as defined under Multilateral Instrument 61-101, Protection of Minority Securityholders in Special Transactions. The issuance of settlement shares, as it relates to Mr. Liu, is exempt from the minority approval and formal valuation requirements of MI 61-101 pursuant to subsections 5.5(a) and 5.7(1)(a) of MI 61-101.

The settlement shares will be subject to a statutory hold period of four months and one day from the date of issuance under applicable securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

The company also clarifies that Mr. Liu's appointment as Chief Executive Officer and Director became effective on Feb. 3, 2025, not Jan. 31, 2025, as previously stated in the Feb. 3, 2025, news release.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Daniel Liu
Chief Executive Officer
Telephone: (650) 676-9562

Item 9. Date of Report

February 7, 2025